Quick definition and key takeaways
- What is tesamorelin? A lab-made analog of the body’s GHRH that increases endogenous growth hormone and IGF-1.
- Approved use: Reduction of visceral abdominal fat in adults with HIV-associated lipodystrophy (brand examples overseas: Egrifta/Egrifta SV).
- Not a general weight loss drug: It is not approved for obesity or cosmetic belly fat reduction.
- Evidence: Randomised trials show meaningful VAT reduction while on therapy; VAT can return after stopping.
- Risks: Injection site reactions, joint/muscle pain, fluid retention, elevated IGF-1, glucose intolerance in some people. Not for those with active malignancy.
What tesamorelin is (and what it is not)
Tesamorelin is a peptide analog of growth hormone–releasing hormone. Rather than providing growth hormone directly, it stimulates your pituitary to release more of your own GH, which in turn increases IGF‑1 and influences fat metabolism. Its clinical niche is the reduction of visceral adipose tissue in adults with HIV‑associated lipodystrophy.
It is not the same as GLP‑1 medicines (like semaglutide or tirzepatide), and it is not approved for general weight loss or bodybuilding. Interest outside its approved use (e.g., abdominal obesity or metabolic syndrome) exists online, but these are off‑label discussions and should be assessed carefully with a qualified clinician.
How tesamorelin works
- Mechanism: Mimics GHRH → increases pituitary GH → raises IGF‑1 → promotes lipolysis and metabolic changes that can reduce visceral fat.
- Target fat: Evidence and approval focus on visceral adipose tissue (VAT), the deep fat around organs, not subcutaneous fat under the skin.
- While on therapy: VAT reduction is generally maintained during treatment; VAT can re‑accumulate after discontinuation.
Evidence at a glance
- Randomised, placebo‑controlled trials in adults with HIV‑associated lipodystrophy demonstrate statistically significant VAT reductions over ~26 weeks on tesamorelin.
- Some studies report improvements in triglycerides and other metabolic markers in subsets of patients, though findings can vary.
- Upon stopping therapy, VAT tends to re‑accumulate, suggesting continued treatment is needed to maintain effect.
- IGF‑1 typically increases during therapy and requires monitoring.
- Glucose intolerance can occur; people at risk for diabetes require careful assessment and monitoring.
Who tesamorelin may be for (and who should avoid it)
May be considered
- Adults with HIV-associated lipodystrophy and excess visceral fat confirmed by clinical assessment and imaging.
- Patients under specialist care who can be appropriately monitored (IGF‑1, glucose, response, adverse events).
Generally not suitable
- People seeking general weight loss or cosmetic fat reduction.
- Those with active malignancy or disrupted hypothalamic‑pituitary function.
- Pregnancy: not recommended; discuss contraception and planning with a clinician.
Dosing and administration basics
Clinical protocols for tesamorelin typically involve a once‑daily subcutaneous injection (commonly 2 mg) into the abdomen with rotation of injection sites. Products are supplied as a powder for reconstitution with a provided diluent and require proper storage and handling.
Specific recommendations vary by patient, brand presentation and clinician guidance. Do not change, start or stop therapy without medical supervision.
Safety, side effects and monitoring
- Common: Injection site reactions, joint pain, muscle aches, swelling (peripheral oedema), tingling, nausea, headache.
- Metabolic: Increased IGF‑1 is expected; glucose intolerance or diabetes can occur in some patients.
- Serious considerations: Not for use with active cancers; evaluate prior malignancies carefully with specialists. Avoid if hypothalamic‑pituitary axis is disrupted.
- Monitoring: IGF‑1, glucose/HbA1c, lipids and clinical response are commonly monitored.
Access and legal status in Australia
Tesamorelin is a prescription‑only medicine. As it is not registered for general supply by the TGA, access may occur under regulated pathways such as the Special Access Scheme (SAS) or the Authorised Prescriber framework. Suitability, documentation and dispensing arrangements are determined by the prescriber and pharmacy within Australian regulations.
- Discuss your clinical history and goals with a qualified Australian prescriber.
- Expect structured monitoring if therapy is initiated.
- Be cautious of overseas or grey‑market products claiming “no prescription required.”
Tesamorelin vs other peptide options
- Tesamorelin vs Sermorelin – VAT reduction in HIV lipodystrophy vs general GH support goals.
- Tesamorelin vs Ipamorelin – Indication‑driven VAT focus vs broader GH secretagogue interest.
Related “What is…?” explainers for context:
Frequently asked questions
What is tesamorelin in simple terms?
A synthetic GHRH analog that increases your own growth hormone and IGF‑1 to help reduce visceral fat in adults with HIV‑associated lipodystrophy.
Is tesamorelin a weight loss medication?
No. It is not approved for general weight loss or cosmetic fat reduction. Its evidence‑based use targets visceral fat in HIV‑associated lipodystrophy.
How is tesamorelin given?
Typically as a once‑daily subcutaneous injection into the abdomen with rotation of injection sites. See the Dosage Guide for details.
How long until I might see changes?
Clinical studies show measurable VAT changes around 3–6 months, maintained during treatment. VAT often returns after stopping.
What are the main risks?
Injection site reactions, joint/muscle pain, fluid retention, tingling, nausea, higher IGF‑1 and potential effects on glucose. People with active cancers should not use it. Discuss your personal risk profile with a clinician.
How do I access tesamorelin in Australia?
It is prescription‑only. As it is not TGA‑registered for general supply, access may occur via SAS or Authorised Prescriber pathways. Work with an Australian prescriber familiar with the regulations.
Final takeaway
Tesamorelin is a GHRH analog with an evidence‑based role in reducing visceral fat among adults with HIV‑associated lipodystrophy. It is not a general weight loss therapy. If you are exploring tesamorelin in Australia, speak with a qualified prescriber about eligibility, monitoring and lawful access pathways.
Have questions about tesamorelin? Get help
Complete the form below and we’ll connect you with information or a qualified Australian provider who can assess your situation. We do not sell medications.